Business Context and Reporting Period
This Form 8-K Current Report was filed by Revolution Medicines, Inc. on June 18, 2025. The report discloses a corporate governance event involving the resignation of a director effective immediately prior to the Company's 2025 annual meeting of stockholders scheduled for June 26, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance data.
Material Changes
The material change reported is the resignation of Barbara Weber, M.D., from the Board of Directors. Dr. Weber also resigned from her roles on the Nominating and Corporate Governance Committee and the Research & Development Committee. The filing states this departure was not the result of any disagreement with the Company regarding operations, policies, or practices.
Outlook, Risks, and Management Commentary
Management commentary indicates that Dr. Weber's resignation is in connection with the activation of a clinical study under an ongoing collaboration between Revolution Medicines and Tango Therapeutics, Inc. No specific financial guidance, new risks, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the status of the collaboration with Tango Therapeutics, Inc. and the specific clinical study mentioned as the reason for the resignation.
- Confirm the timeline for the appointment of a new director to replace Dr. Weber, if applicable.
- Review the Company's upcoming 2025 annual meeting materials for any further updates on board composition.